Gene Therapy on the Horizon for Age-Related Macular Degeneration: What it Means for the IRD Community
For individuals and families navigating the challenges of inherited retinal diseases (IRDs), advancements in gene therapy offer immense hope. While many IRDs are distinct from age-related macular degeneration (AMD), the progress in gene therapy for common conditions like AMD often paves the way for broader applications and improved understanding of retinal treatments. A recent article in Ophthalmology Times Europe highlights the exciting developments in gene therapy for AMD, suggesting a future with potentially more durable and less burdensome treatments for vision loss.
Age-related macular degeneration is a leading cause of irreversible vision loss globally, projected to affect nearly 290 million people by 2040. Current standard treatments for neovascular (wet) AMD, such as anti-VEGF injections, have revolutionized care over the past two decades by reducing abnormal blood vessel growth. However, these treatments often require frequent injections, sometimes monthly or bimonthly, which can be a significant burden for patients and healthcare systems.
Gene therapy is emerging as a promising alternative, aiming to provide sustained therapeutic effects and reduce the need for frequent injections. This approach involves delivering genetic material to retinal cells, instructing them to produce therapeutic proteins that can combat the disease. Several gene therapy candidates for AMD are currently in advanced stages of clinical trials. For example, RGX-314 (from Regenxbio), an AAV8-based gene therapy, is in Phase 3 trials and has shown potential for sustained VEGF suppression, which could reduce the treatment burden.
Delivery methods for gene therapy include intravitreal injection, which is minimally invasive, and subretinal injection, which directly targets the retinal pigment epithelium (RPE) and photoreceptor cells for high efficiency. Suprachoroidal injection is also being explored as a less invasive delivery route. These advancements in vector design, gene targets, and delivery methods are continuously improving the feasibility and efficacy of gene therapy for AMD.
For patients and families in the IRD community, these developments are highly relevant. The success and challenges encountered in developing gene therapies for AMD can inform and accelerate research for other retinal conditions, including rare inherited forms. The approval of Luxturna for Leber congenital amaurosis in 2017 demonstrated the potential of gene therapy in ophthalmology, opening doors for its application to both inherited and common retinal diseases. The ongoing clinical trials for AMD gene therapies, with some showing up to four years of sustained treatment effects, offer a glimpse into a future where long-term vision protection might be achieved with fewer interventions.
While challenges remain, including ensuring safety, addressing immunogenicity, and navigating long-term side effects and manufacturing, the continued progress in gene therapy for AMD suggests a future where more durable and effective treatments could transform the lives of those living with vision loss.